The European Medicines Agency has published a revised reflection paper setting out updated guidance on the use of real-world data
EMA publishes updated reflection paper on RWD use in non-interventional studies Read Post »
The FDA has published draft guidance addressing the use of artificial intelligence and machine learning tools in drug development contexts
FDA issues draft guidance on AI/ML in drug development using real-world data Read Post »
The pharmaceutical industry has reached an inflection point. Real-world evidence isn’t a nice-to-have anymore—it’s the foundation for every major strategic
Here’s a conversation I have more often than you’d think. A VP of Market Access — smart, experienced, absolutely knows
You’re the Head of Market Access at a 200-person specialty biotech. Your lead asset is 18 months from a potential
Here’s what keeps commercial analytics teams up at night: you’re trying to size a market opportunity for a specialty drug
Transforming Pharma Market Sizing With Real-World Insurance Claims Data Read Post »
The GLP-1 market just crossed a threshold most pharma executives didn’t see coming this fast. We’re talking about a therapeutic
Obesity and GLP-1 Insights: Real-World Claims Data for Pharma Read Post »
Here’s what keeps pharma commercial leaders up at night: You’re staring at a $2.6 billion R&D investment for a first-in-class
AI-Driven Pharmaceutical Analytics and Forecasting for New Product Planning Read Post »
Real World Data in Pharma 2026: The Strategic Guide to RWD, RWE, and Synthetic Data If you’re leading product planning
Unlock Pharma Insights with RWD Medical: Real-World and Synthetic Data Read Post »
